The Food and Drug Administration (FDA) approved Merck’s monoclonal antibody shot against respiratory syncytial virus (RSV) for infants up to one year of age.
“ENFLONSIA is a preventive, long-acting monoclonal antibody (mAb) designed to provide direct, rapid and durable protection through 5 months, a typical RSV season, with the same 105 mg dose regardless of weight,” Merck stated.
Children’s Health Defense warned the monoclonal antibody shot had a staggering 11.71% serious adverse event rate.
Trending: Senate Republican leadership looks to limit ability of judges to block federal policies
“These included febrile convulsions, seizures, facial paralysis and brain injury at about three times the rate in the vaccine group (25 of 2,409) as the placebo group (4 of 1,202),” Children’s Health Defense wrote.
FDA Greenlights Merck’s RSV Shot for Newborns — Clinical Trials Showed 11.71% Rate of Serious
Join the conversation!
Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!